Ibrance (palbociclib) vs Trodelvy (sacituzumab govitecan-hziy)
Ibrance (palbociclib) vs Trodelvy (sacituzumab govitecan-hziy)
Ibrance (palbociclib) is a CDK4/6 inhibitor used primarily in combination with hormonal therapies for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, aiming to slow down the progression of the disease by inhibiting cell division. Trodelvy (sacituzumab govitecan-hziy), on the other hand, is an antibody-drug conjugate specifically indicated for the treatment of metastatic triple-negative breast cancer (TNBC) after at least two prior therapies for metastatic disease, and it works by delivering a cytotoxic drug directly to cancer cells. The choice between Ibrance and Trodelvy would largely depend on the specific type of breast cancer a patient has, as well as their previous treatments, with Ibrance being more suitable for HR-positive, HER2-negative breast cancers and Trodelvy being an option for patients with TNBC.
Difference between Ibrance and Trodelvy
Metric | Ibrance (palbociclib) | Trodelvy (sacituzumab govitecan-hziy) |
---|---|---|
Generic name | Palbociclib | Sacituzumab govitecan-hziy |
Indications | Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer | Metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer |
Mechanism of action | CDK4/6 inhibitor, halting cell cycle progression | Antibody-drug conjugate targeting TROP-2 for delivering cytotoxic drug |
Brand names | Ibrance | Trodelvy |
Administrative route | Oral | Intravenous |
Side effects | Neutropenia, leukopenia, infections, fatigue | Neutropenia, diarrhea, nausea, fatigue, anemia, vomiting |
Contraindications | Hypersensitivity to palbociclib or any of its excipients | Hypersensitivity to sacituzumab govitecan-hziy or any of its excipients |
Drug class | Antineoplastic agent, kinase inhibitor | Antineoplastic agent, antibody-drug conjugate |
Manufacturer | Pfizer | Gilead Sciences, Inc. |
Efficacy
Efficacy of Ibrance (Palbociclib) in Breast Cancer
Ibrance (palbociclib) is a targeted therapy known as a cyclin-dependent kinase (CDK) 4/6 inhibitor used for the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The efficacy of Ibrance has been demonstrated in multiple clinical trials. In these studies, Ibrance, when used in combination with letrozole or fulvestrant, has been shown to significantly improve progression-free survival (PFS) compared to letrozole or fulvestrant alone. This improvement in PFS indicates that Ibrance can effectively slow the progression of the disease in the indicated patient population.
Efficacy of Trodelvy (Sacituzumab Govitecan-hziy) in Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy has shown a significant improvement in overall survival (OS) and progression-free survival (PFS) in this patient population. Clinical trials have demonstrated that patients treated with Trodelvy had a median OS that was notably longer compared to those who received standard chemotherapy. Additionally, a higher objective response rate (ORR) was observed in patients treated with Trodelvy, indicating a greater proportion of patients experienced significant tumor shrinkage.
Comparative Efficacy in Breast Cancer Treatment
While both Ibrance and Trodelvy are used in the treatment of breast cancer, their indications and mechanisms of action differ. Ibrance is used primarily for HR+, HER2- breast cancer and works by inhibiting enzymes that are crucial for cell cycle progression, thereby slowing down the growth of cancer cells. On the other hand, Trodelvy is used for patients with TNBC, a type of cancer that does not express hormone receptors or HER2, and it works by delivering a cytotoxic drug directly to the cancer cells. The efficacy of these drugs is dependent on the specific subtype of breast cancer being treated, and they represent important options in the management of breast cancer with differing profiles of activity.
Conclusion
In conclusion, both Ibrance (palbociclib) and Trodelvy (sacituzumab govitecan-hziy) have shown significant efficacy in the treatment of different subtypes of breast cancer. Ibrance has been effective in improving progression-free survival in HR+, HER2- breast cancer when used in combination with other endocrine therapies. Trodelvy has extended overall survival and improved response rates in patients with metastatic triple-negative breast cancer who have previously undergone multiple treatments. These medications are valuable additions to the therapeutic arsenal against breast cancer, offering hope for improved outcomes in patients with these challenging conditions.
Regulatory Agency Approvals
Ibrance
Trodelvy
Access Ibrance or Trodelvy today
If Ibrance or Trodelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us